INBX - Inhibrx Inc.

-

$undefined

N/A

(N/A)

Inhibrx Inc. NasdaqGS:INBX Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Location: 11025 North Torrey Pines Road, La Jolla, La Jolla, CA, 92037, United States | Website: https://inhibrx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

89.05M

Cash

216.5M

Avg Qtr Burn

-41.81M

Short % of Float

9.81%

Insider Ownership

27.19%

Institutional Own.

68.12%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Ozekibart (INBRX-109) (DR5 agonist) Details
Solid tumor/s, Cancer, Chondrosarcoma

Susp. Mover™

Phase 2

Data readout

Ozekibart (INBRX-109) (DR5 agonist) Details
Relapsed/refractory Ewing sarcoma

Phase 1

Data readout

Phase 1

Data readout

Ozekibart (INBRX-109) + FOLFIRI Details
Cancer, Colorectal cancer , Metastatic colorectal cancer

Phase 1

Data readout

Failed

Discontinued